anti-CD19 CAR-NK is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Second Affiliated Hospital, School of Medicine, Zhejiang University, with a possible patent signal linked through modality_match. Manual review is still required.
Target: CD19
Cell type: NK_CELL
Indications: B-cell Non Hodgkin Lymphoma
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Institution: Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase: Phase1
Status: Unknown
Trial count: 1
Active trials: 0
First posted: May 14, 2021
Last updated: May 14, 2021
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT04887012